Iberdomide has been shown to increase IL-2 production from T cells5 and, in this clinical trial of SLE patients, iberdomide increased serum levels of IL-2 and expanded the Treg population in the blood. The gene discussed is IL2; the disease is systemic lupus erythematosus.